Genmab — Juni 2018
-
God morgen.
-
God morgen
-
@Helge. Hvordan går det med arrangementet til Genmab's nye hovedkvarter. Det ville være dejligt at møde en masse genmabbere og få set de nye faciliteter. ? Og samtidig møde folk som ikke er negative på casen. ( undlad venligst at invitere analytikere
) -
Bibob...Jeg må helt ærligt indrømme jeg har hængt i bremsen. Jeg skriver til Rachel senere i dag.
-
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 http://www.dgap.de/dgap/News/corporate/morphosys-presents-updated-clinical-data-for-anticd-antibody-mor-multiple-myeloma-eha-news-with-additional-features/?newsID=1079175
-
EL> It looks like strong data. Is it somerhing we should be concerned about as Genmab investors?
-
Ok tak Sukker
-
Yes, and data are far from superior. Little better on side effects (neutropenia) and IRR. Median prior therapies 1 more than similar darastudies, but nevetheless dara-pom-dex had 76% pts with >=3 prior therapies and better ORR. Mor202 "mono" (with dex) lower ORR than dara mono. 2 hour infusion shortened to 30 minutes is not bad, but no sc version in sight.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind